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Background: Idiopathic pulmonary fibrosis (IPF) is a progressive disease with median survival from 2 to 7 years.
Palliative care is an important part of patients´ care as lung transplantation is not an option for the majority of
patients. The aim of this study was to describe treatment practices, decision-making and symptoms during end-of-life
care of IPF patients.
Methods: We identified 59 deceased patients from a national prospective IPF cohort study (FinnishIPF) and analyzed
retrospectively their health care documentation during the 6 months that preceded death.
Results: Hospital was the place of death for 47 patients (80 %). A majority of the patients (93 %) were hospitalized for a
mean of 30 days (range 1–96 days) during the last 6 months of their life. Altogether, patients spent 15 % of their last
6 months of life in a hospital. End-of-life decisions and do not resuscitate (DNR) orders were made for 19 (32 %) and 34
(57 %) of the patients, respectively, and 22 (42 %) of these decisions were made≤ 3 days prior to death.
During the final hospital stay, antibiotics were given to 79 % and non-invasive ventilation to 36 % of patients. During
the last 24 h of life, radiologic imaging or laboratory tests were taken in 19 % and 53 % of the hospitalized patients,
respectively. These tests and life prolonging therapies were more common in tertiary hospitals compared to other
places of death. Dyspnea (66 %) and pain (31 %) were the most common symptoms recorded. Opioids were
prescribed to 71 % of the patients during the last week before death.
Conclusions: The majority of IPF patients died in a hospital with ongoing life-prolonging procedures until death. The
frequent use of opioids is an indicator of an intention to relieve symptoms, but end-of-life decisions were still made very
late. Early integrated palliative care with advance care plan could improve the end-of-life care of dying IPF patients.
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Idiopathic pulmonary fibrosis (IPF) is a severe, progres-
sive, chronic disease of unknown cause, seen primarily in
older adults [1]. It is the most common interstitial lung
disorder worldwide with a prevalence of 8.6/100 000
inhabitants in Finland according to a recent study [2].
Although there are some advances in the pharmaco-
logical treatment of IPF and some patients undergo lung
transplantation, IPF is still a disease with high mortality
and morbidity [3, 4]. The median overall survival of IPF* Correspondence: kaisa.rajala@hus.fi
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which is comparable to many malignant disorders [4, 5].
According to a recent interview study the diagnosis of IPF
has a major impact on the daily living and family relation-
ships [6]. The symptom burden is heavy, with shortness of
breath and cough being the most common symptoms [6].
Therefore, current guidelines recommend early-integrated
palliative care to IPF patients in addition to early referrals
to lung transplantation and pharmacological treatment to
decrease lung function decline [7, 8].
Despite of the recommendations of integrated palliative
care there are only a few studies on current end-of-life
(EOL) care practices in patients with advanced IPF. Many
IPF patients die at hospitals, but the contents of the care
during the final days of life is largely unknown [9].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Fig. 1 A flow-chart of the study-population
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IPF patients with special emphasis on symptoms, current
treatment practices, end-of-life decisions and the use of
medical services.
Methods
Study population
All patients recruited to the FinnishIPF study and
deceased until February 2014 were included to this
study. FinnishIPF is a prospectively collected, national
clinical registry study of patients with IPF diagnosed
according to the ATS/ERS 2011/2015 criteria [7]. Patient
recruitment was initiated in 2012 and there were 257
patients in the registry in February 2014. A detailed
description of the FinnishIPF study has been published
earlier [2].
Data collection
In Finland, the majority of IPF patients are diagnosed
and treated in the public sector. Electronic patient
record databases and a comprehensive death registry
enable access to medical data of the patients. The
Finnish public health care consists of primary care with
health centers and general wards, and of specialized care
with secondary and tertiary hospitals. In this study, the
term community hospital refers to a primary care
hospital ward in local health center and tertiary hospital
is defined as central or university hospital with special-
ized care and emergency services.
Deceased patients were identified from the FinnishIPF
registry and death certificates were acquired from
“National Authority for Collecting and Compiling Statis-
tics on various fields of Society and Economy”. We
collected the data concerning the patients last 6 months
of life from medical records of tertiary and community
hospitals including outpatient visits and records of home
care. In addition, documents from private and occupa-
tional health care were evaluated if their use were men-
tioned inpatient records from public health care. In
order to describe patients EOL care, all the given
pharmacological and non-pharmacological treatments,
reported symptoms as well as radiological and laboratory
tests taken were recorded during the final hospital stay
or the last week before death of those who died at home.
The presence of symptoms was retrospectively collected
from medical records. Standardized tools for symptom
scores were not used in clinical practice.
Collected sociodemographic and disease characteris-
tics included: age, sex, date of birth, date of IPF diagno-
sis, date and place of death, co-morbidities and smoking
status. We also collected data of all visits to emergency
room and hospital stays during the last 6 months of life.
Do-not-resuscitate (DNR) orders, EOL decisions, pallia-
tive care specialist consultations and referrals to hospicewere recorded. In the present study we have used the term
“EOL decision” for recorded decisions to start comfort
only EOL care or symptom centered palliative care.Statistics
Characteristics of the patients were reported with
descriptive statistics including means, medians, SDs, and
ranges. X2 –test was used for comparison of categorical
variables between different patient groups. Two-sided
P-value of less than 0.05 was accepted as statistically
significant. Data analysis was done using SPSS version 22.Results
At the end of the observation period (February 2014) 61
patients identified from the FinnishIPF study had died.
Two patients died abroad and were excluded due to
insufficient data for analysis. Thus, 59 deceased patients
formed the final study population (Fig. 1).
Patient characteristics are shown in Table 1. Eight
patients (14 %) died at home, three (5 %) in a nursing
home and one (2 %) in a hospice, whereas 47 (80 %) died
at a hospital (three out of them in intensive care unit
(ICU)). A majority of the patients (93 %) were hospital-
ized for a mean of 30 days (range 1–96 days) during the
last 6 months of their life. Altogether, patients spent
15 % of their last 6 months of life in a hospital.
Table 1 Patient characteristics
No. (%)
Patients 59
Male 32 (54 %)
Age, mean (range) 77 (56–91)
Years from diagnose to death, mean (SD) 3,7 (2,9)
Smoking
Never 26 (44 %)
Former 28 (48 %)
Current 2 (3 %)
Missing data 3 (5 %)
Comorbidities
Cardiovascular disease 40 (68 %)
Hypertension 28 (48 %)
Diabetes mellitus 17 (29 %)
Atrial fibrillation 13 (22 %)
Obstructive lung disease 12 (20 %)
Cancer 10 (17 %)
Comorbidities per patient
None 4 (7 %)
1–2 21 (36 %)
3–4 29 (49 %)
> 5 5 (9 %)
Place of death
Tertiary hospital (ward) 23 (39 %)
Tertiary hospital (ICU) 3 (5 %)
Community hospital 21 (36 %)
Home 8 (14 %)
Hospice 1 (2 %)
Nursing home 3 (5 %)
Cause of death recorded in death certificates
IPF 42 (71 %)
Cardiovascular diseases 7 (12 %)
Cancer 6 (10 %)
Other 4 (7 %)
Hospital admissions during the last 6 months of life,
median (range)
Hospital ward visits 2 (0–6)
Length of stay per visit (days) 11 (1–48)
Length of final stay (days) 9 (1–77)
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had three or more diseases other than IPF. The cause
of death was IPF in the majority of patients. Ten
patients had a diagnosis of cancer (four cases of lung
cancer) and cancer was the primary cause of death in
six patients.DNR-orders and end-of-life decisions
Frequencies and timing of DNR-orders and EOL
decisions are presented in Fig. 2. DNR order and EOL
decision occurred in 34 (57 %) and 19 (32 %) of the pa-
tients, respectively. Fourteen (74 %) of the EOL deci-
sions and 8 (24 %) of the DNR orders were made ≤
3 days prior to death. Six (32 %) EOL decisions were
made during the final 24 h of life. Fourteen (24 %)
patients had both a DNR-order and an EOL decision. In
20 patients (44 %) no documented DNR order nor EOL
decision was found. We didn’t find any records of pallia-
tive care specialist consultations in any of the patients
and only one patient was referred to a hospice.
Symptoms and treatments during the last week of life
Symptoms and symptom relieving treatments during the
last week of life are shown in Table 2. The most com-
mon symptoms were dyspnea (66 %) and pain (31 %).
Opioids were prescribed to 71 % of the patients, of
which 64 % were on demand short-acting opioids and
36 % long-acting ones. Antidepressants had been pre-
scribed for 25 % of the patients.
Life prolonging treatments during the last week of life
and diagnostic tests during the last day of life in
different care settings are presented in Table 3. Seven
patients (12 %) were resuscitated. Three patients died
in an ICU and two patients were intubated. Most
patients (81 %) received supplemental oxygen, and 17
(29 %) were treated with non-invasive ventilation
(NIV). Life prolonging treatments and diagnostic tests
were common during the last days of life in patients
dying at hospitals. These procedures were more fre-
quent in tertiary hospitals compared to community
hospitals (Table 3).
Discussion
In the present retrospective study we have described the
end of life care of IPF patients. Our results indicate that
DNR orders and end of life decisions were made late in
the patients life span and life-prolonging therapies were
likely to continue until the last days of life.
Due to the unpredictable disease trajectory with some
patients remaining relatively stable, whereas others show
a rapid lung function decline and/or acute exacerbations,
discussions about EOL care preferences and early refer-
ral to palliative care are recommended [7]. In this per-
spective, the current guidelines seem to be poorly
implemented to clinical practice. In a recent register
study [9], end-of-life decisions were commonly made
late in the disease course of IPF and only 14 % of the
patients received referral to palliative care. Even among
patients with very severe oxygen-dependent interstitial
lung diseases (ILD), only 41 % of the patients underwent
EOL discussions [10]. In general, patients suffering from
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Fig. 2 Cumulative number of DNR orders and end-of-life decisions before death in IPF-patients (n = 59)
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compared to lung cancer even though the symptom bur-
den is high in both [10, 11]. This is highlighted in a
recent study by Ahmadi and co-workers who showed
that 19 % of lung cancer patients receive palliative care
team consultation, whereas only 6 % of ILD patients do
so [10]. Only about one third of the patients, in our
study had documented EOL decision and most of them
were made during the last three days of life. No pallia-
tive care consultations were found and referrals to
hospice were very rare, although this may partly reflect
the rarity of these services in Finland. In any case, these
findings from our and previous studies highlight the
need for advanced care plans for IPF-patients. Our
results also indicate, that DNR orders do not affect
treatment practices during the final phase of IPF.
Our patients spent about 15 % of their last 6 months
of life in a hospital and vast majority (80 %) of them also
died there. Roughly half of the IPF-patients are reported
to die in a hospital [9, 10], but our numbers are even
higher. In addition, hospital admissions during the final
months of life exceeded those reported in cancer [12].Table 2 Reported symptoms and symptom relieving
medication during the last 7 days of life
Symptoms Number (%)
Breathlessness 39 (66 %)
Pain 18 (31 %)
Delirium 11 (19 %)
Anxiety/depression 10 (17 %)
Cough 9 (15 %)
Nausea 4 (7 %)
Constipation 1 (2 %)
Medication
Opioids 42 (71 %)
Anxiolytics 26 (44 %)The most probable reason for this result is the lack of
advance care plans and limited use of palliative care ser-
vices and home hospice care for non-malignant diseases.
Nevertheless, these findings do not comply with patients’
wishes as most of the patients with life-limiting diseases,
including IPF, prefer to be treated and die at home or a
hospice [13]. Advanced care planning and arrangement
of palliative home care have shown to reduce emergency
room visits, hospital stays and dying in hospital setting
among patients with multiple end-stage diseases [14].
Similar benefits could be achieved by early-integrated
palliative care in IPF.
To our knowledge, this is the first study to describe
EOL treatment practices in a registry-based population
of IPF-patients. We found procedures intended to pro-
long life (e.g. laboratory tests, NIV and prescribing anti-
biotics) to be relatively common during the final days,
although symptoms were treated (e.g. prescribing
opioids) at the same time. This dual approach to a dying
IPF-patient was probably due to the difficulty to differ-
entiate exacerbation, secondary infection and a dying
patient, but – again - also due to a late EOL decision.
In the present population one third of the patients
received NIV treatment during the last week of life. NIV
may relieve dyspnea as a palliative treatment, but in acute
care, it is mostly used to improve survival in chronic
obstructive pulmonary disease exacerbation [15–17]. The
benefit of the use of NIV the symptomatic therapy of IPF
patients has not been proven and, therefore, NIV is not
routinely recommended [18]. Although it is understand-
able that NIV is used in a hope for cure or in order to
relieve breathlessness, using a mask may increase and
prolong suffering of the patient and prevent communica-
tion with closest ones. Therefore, the pros and cons of
NIV in patients with end-stage IPF should be carefully
considered. In contrast to NIV, oxygen therapy is recom-
mended to IPF patients with hypoxemia [1]. Thus, it’s not
surprising that majority of our patients received oxygen.
Table 3 Life prolonging treatments and diagnostic tests during the last week of life
Place of death
Tertiary hospital Community hospital Home, nursing home or hospice Total
Number of patients 26 21 12 59
Life prolonging treatments (last 7 days)
NIV 13 (50 %) 4 (19 %)* 0 17 (29 %)
Parenteral fluids 16 (62 %) 11 (52 %) 2 (16 %) 29 (49 %)
Antibiotics 24 (92 %) 13 (62 %)* 2 (16 %) 39 (66 %)
Diagnostic tests (last 24 h)
X-rays 8 (31 %) 1 (5 %)* 0 9 (15 %)
Laboratory tests 18 (69 %) 7 (33 %)* 0 25 (42 %)
NIV non-invasive ventilation
* p < 0.05 for tertiary vs. community hospital
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were ordered during the last 24 h of life and antibiotics
were commonly prescribed near death. Death related to
IPF is typically respiratory failure related to either
progression of the disease or acute exacerbation. The
clinical picture of acute exacerbation is not easily
distinguished from bacterial pneumonia (elevation of
c-reactive protein and pulmonary infiltrates) [19, 20].
Thus, treatment attempts with bacterial antibiotics
found in our study are understandable and frequent
antibiotic use is also common in patients with COPD
and lung cancer during the final days of life [21].
However, the benefit of antimicrobial therapies and
ordering multiple diagnostic tests should be reconsid-
ered if the presumable prognosis of the patient is very
poor (e.g. when the patient is bed-bound and highly
dependent on oxygen therapy). In our population, 66 %
of the patients received antibiotics during last week of life.
Although these factors are not necessary indicators of
poor EOL care, they reflect life-prolonging nature of the
treatment close to death.
In our study, shortness of breath (66 %) and pain
(31 %) were the two most common symptoms reported.
In a retrospective study of ILD, shortness of breath
occurred in 93 % and chest pain in 29 % of the patients,
while many other symptoms like depression and fatigue
were found as well [13]. In a recent study by Ahmadi
et al. breathlessness (75 %), anxiety (66 %) and pain
(51 %) were the most common symptoms in a mixed
population of ILD patients [10]. The difference in the
incidences of these symptoms may be due the retro-
spective nature of our study. The point of gravity in
clinical patient handling may not be in the symptom-
reporting, if compared to ie. questionnaire studies of
clinical trials. Standardized symptom scores were not –
unfortunately – a part of the evaluation of our patients.
This is an important issue that should maybe be addressed
in future guidelines on patient follow-up. As in other
advanced lung diseases, breathlessness is obviously the mainsymptom in IPF. In contrast, the cause and nature of pain
in IPF is unknown. This is beyond the scope of our study,
but should be evaluated in future studies. Of interest,
cough was reported in only 15 % of our patients, which is
less than in previous studies [13]. We suggest that cough
was either not very severe symptom in dying IPF-patients
or health care professionals did not record the symptom.
In the present study, opioids were more frequently used
than in a previous study [13]. No controlled trials support
the use of opioids for shortness of breath in IPF, but there
is relatively good evidence about their benefit in refractory
dyspnea in general [18, 22, 23]. Therefore, the common
use of opioids probably reflects a great need to control
breathlessness in the dying IPF-patient. In addition, pain
relief could be another reason for prescribing opioids,
since nearly one-third of our patients suffered from pain.
In a Swedish study anxiety was more common (66 %) in
ILD patients compared to our study (17 %), but still a
significant proportion of our patients had received antide-
pressants (25 %) and anxiolytics (44 %) [10] We suggest
that psychological symptoms were not systematically
recorded in patient charts, although they probably existed.
Our study is limited by a relatively small number of
patients. Other limitations are the lack of more detailed
information about the nature of the EOL decisions and
the lack of systematic collection of patient-reported
symptoms. The strength of the study is that the results
represent a real-life IPF population, as most of the
patient charts were identifiable from national registries.Conclusions
The majority of IPF patients die in a hospital setting.
Death seems to be unpredictable in many cases. The late
EOL decisions and the aggressive nature of the treat-
ment during the final days reflect an unforeseeable
approaching death and unplanned palliative care.
Advance care plans and early EOL discussions could
improve the palliative care of IPF patients.
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